

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: ALB2/22 - Albumin in Urine

Deadline: 14.10.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
		RoM	SD	CV [%]	N _{tot}	N _{out}									
(369) Albumin											248	230	93%		
Samples and groups	[mg/L]														
Sample A		60,3	4,8	8,0	248	CVP	60,3	0,75	21%	47,6	73	248	242	98%	
(1) Abbott		64,1	2,5	3,9	62	0						62			
(12) Beckman Coulter		59,2	2,9	4,9	5	0						5			
(58) Beckman Coulter (AU)		61,9	2,2	3,5	39	0						39			
(60) Roche		58,3	3,3	5,7	90	0						90			
(162) Siemens (Atellica)		54,5	2,0	3,7	14	0						14			
(179) Siemens		56,1	2,9	5,2	15	0						15			
Other					23	0						23			
							1x 0, 1x 5, 1x 36, 1x 46, 3x 49, 3x 75, 1x 91, 1x 116, 3x 149, 3x 152, 3x 177, 1x 178, 1x 999								
Sample B		14,8	1,5	10	248	CVP	14,8	0,24	30%	10,3	19,3	248	232	94%	
(1) Abbott		16,1	0,84	5,2	62	0						62			
(12) Beckman Coulter		14,7	0,052	0,35	5	0						5			
(58) Beckman Coulter (AU)		14,8	0,73	4,9	39	0						39			
(60) Roche		14,9	0,67	4,5	90	0						90			
(162) Siemens (Atellica)		10,9	0,52	4,8	14	0						14			
(179) Siemens		11,8	1,4	12	15	0						15			
Other					23	0						23			
							1x 0, 1x 5, 1x 36, 1x 46, 3x 49, 3x 75, 1x 91, 1x 116, 3x 149, 3x 152, 3x 177, 1x 178, 1x 999								
(408) Creatinine												236	231	98%	
Samples and groups	[mmol/L]														
Sample A		11,7	0,55	4,7	236	CVP	11,7	0,087	16%	9,82	13,6	236	233	99%	
(0) not specified		11,4	0,29	2,5	5	0						5			
(1) Abbott		11,4	0,44	3,9	55	0						55			
(46) Erba Lachema		12,2	0,90	7,3	10	0						10			
(58) Beckman Coulter (AU)		12,0	0,60	5,0	39	0						39			
(60) Roche		11,8	0,54	4,6	87	0						87			
(162) Siemens (Atellica)		11,5	0,23	2,0	15	0						15			
(179) Siemens		12,0	0,50	4,1	14	0						14			
Other					11	0						11			
							2x 5, 1x 12, 1x 49, 2x 116, 1x 158, 2x 177, 1x 178, 1x 196								
Sample B		5,85	0,28	4,8	236	CVP	5,85	0,045	16%	4,91	6,79	236	233	99%	
(0) not specified		5,76	0,13	2,3	5	0						5			
(1) Abbott		5,72	0,20	3,5	55	0						55			
(46) Erba Lachema		6,03	0,46	7,6	10	0						10			
(58) Beckman Coulter (AU)		5,86	0,37	6,3	39	0						39			
(60) Roche		5,94	0,28	4,7	87	0						87			
(162) Siemens (Atellica)		5,79	0,097	1,7	15	0						15			
(179) Siemens		5,93	0,21	3,5	14	0						14			
Other					11	0						11			
							2x 5, 1x 12, 1x 49, 2x 116, 1x 158, 2x 177, 1x 178, 1x 196								
(470) ACR												232	213	92%	
Samples and groups	[g/mol]														
Sample A		5,13	0,54	11	232	CVP	5,13	0,087	24%	3,89	6,37	232	224	97%	
(0) not specified		5,13	0,54	11	232	0						232			
Sample B		2,53	0,35	14	232	CVP	2,53	0,056	30%	1,77	3,29	232	217	94%	
(0) not specified		2,53	0,35	14	232	0						232			

st_kn_p

End of report

Printed: 21.10.2022